Stephen Rainer
St. Vincent's Health System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stephen Rainer.
Journal of Clinical Investigation | 2004
Vesna Nikolova; Christiana Leimena; Aisling C. McMahon; Ju Chiat Tan; Suchitra Chandar; Dilesh Jogia; Scott H. Kesteven; Jan Michalicek; Robyn Otway; Fons Verheyen; Stephen Rainer; Colin L. Stewart; David H. Martin; Michael P. Feneley; Diane Fatkin
Laminopathies are a group of disorders caused by mutations in the LMNA gene that encodes the nuclear lamina proteins, lamin A and lamin C; their pathophysiological basis is unknown. We report that lamin A/C-deficient (Lmna(-/-)) mice develop rapidly progressive dilated cardiomyopathy (DCM) characterized by left ventricular (LV) dilation and reduced systolic contraction. Isolated Lmna(-/-) myocytes show reduced shortening with normal baseline and peak amplitude of Ca(2+) transients. Lmna(-/-) LV myocyte nuclei have marked alterations of shape and size with central displacement and fragmentation of heterochromatin; these changes are present but less severe in left atrial nuclei. Electron microscopy of Lmna(-/-) cardiomyocytes shows disorganization and detachment of desmin filaments from the nuclear surface with progressive disruption of the cytoskeletal desmin network. Alterations in nuclear architecture are associated with defective nuclear function evidenced by decreased SREBP1 import, reduced PPARgamma expression, and a lack of hypertrophic gene activation. These findings suggest a model in which the primary pathophysiological mechanism in Lmna(-/-) mice is defective force transmission resulting from disruption of lamin interactions with the muscle-specific desmin network and loss of cytoskeletal tension. Despite severe DCM, defects in nuclear function prevent Lmna(-/-) cardiomyocytes from developing compensatory hypertrophy and accelerate disease progression.
Journal of Heart and Lung Transplantation | 2002
Peter Hopkins; Christina L. Aboyoun; Prashant N. Chhajed; M.A. Malouf; M. Plit; Stephen Rainer; Allan R. Glanville
OBJECTIVE Fiber-optic bronchoscopy with multiple transbronchial lung biopsies (TBB) is the gold standard of evaluation of the pulmonary allograft post-lung transplantation (LT). However, controversy exists regarding the need for surveillance procedures and number of biopsy specimens required for satisfactory yield. The potential morbidity in obtaining multiple TBB specimens remains poorly described. We report the largest series of TBB in LT recipients to date, highlighting the occurrence of acute rejection and infection for surveillance and diagnostic procedures. The safety of TBB is analyzed and a biopsy schedule proposed. METHODS Prospective analysis of 1,235 TBB in 230 LT recipients performed at St Vincents Hospital from January 1995 to June 2000. RESULTS Eight hundred thirty-six (67.7%) TBB were performed as surveillance and 399 (32.3%) for a clinical indication. No significant acute rejection (AR) or infection was disclosed in 53.3% of procedures. The Lung Rejection Study Group requirement of at least five pieces of evaluable lung parenchyma was achieved in 98.2% of procedures. The average number of evaluable fragments per procedure was 6.4, whereas only 3 TBB (0.24%) contained no lung parenchyma and 44 (3.6%) no bronchial wall. Histologic features of AR, lymphocytic bronchiolitis or infection were found in 18.9% of surveillance and 86.4% of clinical TBBs. The yield of surveillance procedures between 4 and 12 months was just 1.1% for cytomegalovirus and 6.1% for AR. The overall complication rate was 6.35% with no deaths recorded. CONCLUSION Taking 10 to 12 TBB specimens has a high diagnostic yield and rarely fails to provide adequate tissue. The role of surveillance procedures post-lung transplantation remains controversial.
Circulation Research | 2010
Suchitra Chandar; Li Sze Yeo; Christiana Leimena; Ju-Chiat Tan; Xiao-Hui Xiao; Vesna Nikolova-Krstevski; Yoshinori Yasuoka; Margaret Gardiner-Garden; Jianxin Wu; Scott H. Kesteven; Lina Karlsdotter; Shweta Natarajan; Arthur Carlton; Stephen Rainer; Michael P. Feneley; Diane Fatkin
Rationale: Mutations in the LMNA gene, which encodes the nuclear lamina proteins lamin A and lamin C, are the most common cause of familial dilated cardiomyopathy (DCM). Mechanical stress-induced apoptosis has been proposed as the mechanism underpinning DCM in lamin A/C–deficient hearts, but supporting in vivo evidence has been lacking. Objective: Our aim was to study interventions to modify mechanical stress in heterozygous Lmna knockout (Lmna+/−) mice. Methods and Results: Cardiac structure and function were evaluated before and after exercise training, thoracic aortic constriction, and carvedilol treatment. Lmna+/− mice develop adult-onset DCM with relatively more severe disease in males. Lmna+/− cardiomyocytes show altered nuclear morphology and perinuclear desmin organization, with enhanced responses to hypo-osmotic stress indicative of cytoskeletal instability. Despite these structural defects that provide a template for mechanical stress-induced damage, young Lmna+/− mice subjected to 6 weeks of moderate or strenuous exercise training did not show induction of apoptosis or accelerated DCM. In contrast, regular moderate exercise attenuated DCM development in male Lmna+/− mice. Sustained pressure overload generated by thoracic aortic constriction depressed ventricular contraction in young wild-type and Lmna+/− mice with no sex or genotype differences in the time-course or severity of response. Treatment of male Lmna+/− mice from 12 to 40 weeks with the &bgr;-blocker, carvedilol, prevented the dilatation and contractile dysfunction that was observed in placebo-treated mice. Conclusions: These data suggest that factors other than mechanical stress-induced apoptosis contribute to DCM and provide the first demonstration that regular moderate exercise and carvedilol can modify disease progression in lamin A/C–deficient hearts.
Journal of the American College of Cardiology | 2015
Leah Cannon; Ze-Yan Yu; Tadeusz Marciniec; Ashley J. Waardenberg; Siiri E. Iismaa; Vesna Nikolova-Krstevski; Elysia Neist; Monique Ohanian; Min Ru Qiu; Stephen Rainer; Richard P. Harvey; Michael P. Feneley; Robert M. Graham; Diane Fatkin
BACKGROUND Hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein genes, and left ventricular hypertrophy (LVH) develops as an adaptive response to sarcomere dysfunction. It remains unclear whether persistent expression of the mutant gene is required for LVH or whether early gene expression acts as an immutable inductive trigger. OBJECTIVES The aim of this study was to use a regulatable murine model of HCM to study the reversibility of pathological LVH. METHODS The authors generated a double-transgenic mouse model, tTAxαMHCR403Q, in which expression of the HCM-causing Arg403Gln mutation in the α-myosin heavy chain (MHC) gene is inhibited by doxycycline administration. Cardiac structure and function were evaluated in groups of mice that received doxycycline for varying periods from 0 to 40 weeks of age. RESULTS Untreated tTAxαMHCR403Q mice showed increased left ventricular (LV) mass, contractile dysfunction, myofibrillar disarray, and fibrosis. In contrast, mice treated with doxycycline from conception to 6 weeks had markedly less LVH and fibrosis at 40 weeks. Transgene inhibition from 6 weeks reduced fibrosis but did not prevent LVH or functional changes. There were no differences in LV parameters at 40 weeks between mice with transgene inhibition from 20 weeks and mice with continuous transgene expression. CONCLUSIONS These findings highlight the critical role of the early postnatal period in HCM pathogenesis and suggest that mutant sarcomeres manifest irreversible cardiomyocyte defects that induce LVH. In HCM, mutation-silencing therapies are likely to be ineffective for hypertrophy regression and would have to be administered very early in life to prevent hypertrophy development.
American Journal of Respiratory and Critical Care Medicine | 2004
Peter Hopkins; Christina L. Aboyoun; Prashant N. Chhajed; M.A. Malouf; M. Plit; Stephen Rainer; Allan R. Glanville
American Journal of Respiratory and Critical Care Medicine | 2004
Michael Tamm; Christina L. Aboyoun; Prashant N. Chhajed; Stephen Rainer; M.A. Malouf; Allan R. Glanville
American Journal of Respiratory and Critical Care Medicine | 2001
Christina L. Aboyoun; Michael Tamm; Prashant N. Chhajed; Peter Hopkins; M.A. Malouf; Stephen Rainer; Allan R. Glanville
Australian and New Zealand Journal of Surgery | 1996
Eddie Yeung; Thomas B. Hugh; Stephen Rainer
Journal of Heart and Lung Transplantation | 2007
Allan R. Glanville; Christina L. Aboyoun; A. Havryk; M. Plit; Stephen Rainer; M.A. Malouf
The Lancet | 2015
Louis W. Wang; Abdullah Omari; Louise Emmett; P. Jansz; Ravi L. Huilgol; Stephen Rainer; Rajesh N. Subbiah